The DNA/rAd5 vaccine regimen (HVTN 505) did not reduce either the rate of HIV-1 infection or the viral-load set point although robust CD8+ T cell responses were elicited.22 The immune response characteristics of DNA-rTV are similar to those induced in RV144 trial, including high binding antibodies, multifunctional CD4+ response, and absence of neutralizing antibodies.23 While lacking the V1V2-specific IgG3 associated with partial efficacy observed in RV144 trial, DNA-rTV induces dominant polyfunctional CD4+ T-cell responses with sustained durability. The gene discussed is CD8A; the disease is HIV-1 infection.